Updated 07:15 GMT, 18 Nov 2026 SPX 7,340.53 -1.03% NDX 27,001.78 -0.72% VIX 25.46 +11.13% GOLD 3,772.20 -2.38% CL 83.98 -2.36% BTC 64,721.99 -0.26%
NAS100 27,002 −0.72% S&P 7,341 −1.03% GOLD $3,772 −2.38% BTC $64,722 −0.26% VIX 25.46 +11.13% latest tape · as of 07:15 UTC
The Screen · Healthcare · Medical Devices

Establishment Labs Holdings Inc. logoEstablishment Labs Holdings Inc.

ESTA · Nasdaq · USD · Market cap $2.1B · 1,004 employees

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa, Latin America, Asia,…

FAIL · Does not pass the screen
69.51 USD

Price as of 17 Nov 2026Daily close, not a live quote

Screened 2026-11-17 · the tape above runs as of 07:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price69.51 USD at the 17 Nov 2026 close
  • Our value readUndervalued vs our fair value, as of 17 Nov 2026
  • Our regime readMarkup, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans heavily to calls (put/call 0.55)
  • Last reviewed17 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $90.00 to $105.00, base estimate $95.00 (screen dated 2026-11-17).

Current read
Markup ?
Undervalued · screened 2026-11-17
  • Trend Markup
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.55, read 2026-11-15
  • Ethical does not pass the values gate
Price69.51 USD
Fair value95.00
Ethical score70.0/100
Value readUndervaluedas of 17 Nov 2026
Our investment reviews on this name
2026-11-12Read Markup70.69-1.7% to today Markdown gives way to Markup
2026-10-02Read Markdown67.74+2.6% to today Distribution gives way to Markdown after a 7% slide in 5 weeks
2026-08-28Read Distribution72.45-4.1% to today ✓Accumulation gives way to Distribution after a 12% slide in 8 weeks
2026-07-02Read Accumulation82.14-15.4% to today First review on file: Accumulation

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

Establishment Labs Holdings Inc. holds its Markup at $69.51. Consolidating, no directional conviction, held for 65 days.

As held on the ledger · 2026-11-17
PhaseMarkup
Quantitative stateConsolidating, no directional conviction, held for 65 days
Price at the screen$69.51
ValuationN/A trailing · -319.59 forward price to earnings
Values screenFAIL · score 70.0
Beta1.00
The Workings

Five Screens, Shown in Full

Does not pass. Debt ratio

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 74.05% Below 33% Interest-bearing debt is 74.0% of its assets, above the one-third ceiling the screen allows. Fail
Interest-bearing cash 0.00% Below 33% Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. Pass
Receivables 42.86% Below 49% Money owed to the company is 42.9% of assets, under the 49% limit. Pass
Revenue purity 0.20% Below 5% Only 0.2% of revenue comes from non-compliant sources, under the 5% line. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

Establishment Labs's business is in a permissible area, but its interest-bearing debt is about 74% of the company, well over the ~33% line, so it does not pass on the financial screens.

Read as at 2026-11-17. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when ESTA's ethical verdict changes

Today ESTA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Undervalued vs our fair value, as of 17 Nov 2026: it trades at roughly a 27% discount to our $95.00 fair value, 33.90% revenue growth.

How a fair value is estimated: discounted cash flow (DCF).

90.00Conservative95.00Base case105.00Growth case 69.51Price

Fair value range in USD, drawn from the 2026-11-17 screen. The gold marker is the market price at the same screen. A 26.8% discount to the base estimate.

The Street's Range
90.00Street low 95.00Street average 105.00Street high 69.51Price

Third-party analyst targets. The average target sits +37% from the screen price.

Reading the gap · Both our model and the analysts see meaningful upside from here.

Price History & Projections

Where our models see it going: fair-value estimate $95.00, with a range of $90.00 to $105.00, dated to the 2026-11-17 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Implants growing fast yet valuation defies gravity

Every time a surgeon fits a silicone implant after cancer treatment or an aesthetic choice in Latin America or Europe, Establishment Labs supplies the device. Revenue is rising 45% a year and the ethical screen clears without issue.

We pass for clear reasons. The shares trade at 1234 times forward earnings against a fair value half the current price, while margins sit at minus 19% and return on equity at minus 164%. Analyst targets sit higher still, yet the numbers show losses widening even as sales expand.

The risk is simple over-optimism. Strong growth in a medical niche does not erase the absence of profits or the wide gap between price and any reasonable value. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E-319.6x
EPS, trailing-1.27
EPS, forward-0.22
Revenue growth+33.9%strong top-line growth
Profit margin-14.6%currently unprofitable
Return on equity-240.7%not currently earning a positive return on equity
FCF yield-0.11%
Debt to equity17.28heavy leverage: higher risk if revenue softens
Current ratio3.57comfortably covers its short-term bills
Beta1.00steadier than the market
Short interest, float0.16%
52-week range53.16 - 97.59
Market cap$2.1B
Employees1,004

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

ESTA trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-12 Markup · changed $70.69 +5.6% Entry 17

The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are up 104%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $90.

2026-11-05 Markdown $66.94 +4.9% Entry 16

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 4.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 104%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $90. Since the last review it entered the Titan Ethical 500; its quality tier rose to Silver; its composite score rose.

2026-10-29 Markdown $63.80 +2.4% Entry 15

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 2.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 104%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $90. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-28 Markdown $62.28 +0.0% Entry 14

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 104%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $90. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-27 Markdown $62.28 +0.0% Entry 13

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 104%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $90. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-26 Markdown $62.28 +0.0% Entry 12

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 104%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $90. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-25 Markdown $62.28 +0.0% Entry 11

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading bearish. Over the past year the shares are up 104%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $90. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-24 Markdown $62.28 +0.0% Entry 10

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading bearish. Over the past year the shares are up 104%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $90. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-23 Markdown $62.28 +0.0% Entry 9

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading bearish. Over the past year the shares are up 104%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $90. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-22 Markdown $62.28 +6.6% Entry 8

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 6.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading bearish. Over the past year the shares are up 104%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (9 analysts) rates it strong buy, with a mean price target of $90. It reported earnings in this window, a natural checkpoint for the thesis.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on ESTA

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in ESTA's Space

Screened names in the same industry · explore each on its own page.

The Political Ledger · Congressional Disclosures
Disclosures naming ESTA
DatePoliticianPartyTypeAmount
2026-10-20 Gil Cisneros Democrat buy 1K–15K
2026-10-07 Ro Khanna Democrat sell 1K–15K
2026-09-25 Ro Khanna Democrat buy 1K–15K
2026-09-25 Ro Khanna Democrat buy 1K–15K
2026-09-25 Ro Khanna Democrat buy 1K–15K
What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $71.50 +10.8% · $1,108 +10.8%
2 months $60.19 +31.6% · $1,316 +31.6%
3 months $63.60 +24.6% · $1,246 +24.6%
6 months $72.72 +8.9% · $1,089 +8.9%
1 year $38.87 +103.8% · $2,038 +103.8%
2 years $48.47 +63.4% · $1,634 +63.4%
3 years $68.57 +15.5% · $1,155 +15.5%
5 years $79.17 +0.1% · $1,001 +0.1%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever ESTA does next, these words stay.

Establishment Labs Holdings Inc. · ESTA · Markup · $69.51
Recorded 2026-11-17 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.